EX-99.1 2 ndra_ex991.htm PRESS RELEASE Blueprint
  Exhibit 99.1
 
 
  
ENDRA Life Sciences Provides Business Update and Reports
Third Quarter 2019 Financial Results
 
●
Conference call scheduled for 4:30 p.m. ET today
 
ANN ARBOR, Michigan - November 13, 2019 - ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today provided a business update and reported third quarter 2019 financial results.
 
“ENDRA has made important clinical and operational progress this quarter as we move towards commercialization during 2020,” said Francois Michelon, chairman and chief executive officer. “Completion of part two of the feasibility study at Robarts Research Institute represented a major milestone in the advancement of our pioneering TAEUS technology. Initial findings support our belief that TAEUS is positioned to be a practical tool for use with other biomarkers in the management of NAFLD and NASH at the point of patient care, and we are moving ahead with additional clinical study sites and regulatory filings. We also continue to engage with our key clinical audiences as we ramp up commercialization efforts heading into 2020.”
 
Business Highlights
●
Reported top level findings from part two of the feasibility study at Robarts Research Institute.
●
Showcased the pre-production TAEUS liver device1 for the first time at the Annual 2019 AASLD Liver Meeting.
●
Hosted Key Opinion Leader (KOL) event in conjunction with the Annual 2019 AASLD Liver Meeting featuring a presentation by Dr. Raza Malik, M.D., Ph.D. Director of Hepatology and Associate Chief, Division of Gastroenterology at Tufts Medical Center.
●
Increased intellectual property (IP) portfolio to 60 assets defined, filed and issued.
 
Financial Results for Quarter Ended September 30, 2019
●
Operating expenses increased to $2.6 million in the third quarter of 2019, up from $2.4 million in the third quarter of 2018. The increase in operating expenses was primarily due to expenses related to the development of our TAEUS product line, and costs associated with the pre-commercialization of TAEUS.
●
 Net loss in Q3 2019 totaled $3.4 million, or ($0.46) per basic and diluted share, as compared to a net loss of $2.8 million, or ($0.70) per basic and diluted share in Q3 2018.
●
Cash at September 30, 2019 totaled $2.3 million, as compared to $6.5 million at December 31, 2018, with no long-term debt outstanding.
 
 
 
 
 
Conference Call and Webcast Access
Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide an update on recent corporate developments.
 
Dial-in Number
U.S./Canada Dial-in Number: 844-602-0380
International Dial-in Number: 862-298-0970
Replay Dial-in Number: 877-481-4010
Replay International Dial-in Number: 919-882-2331
Replay Passcode: 56751
 
A telephone replay will be available November 13, 2019 through 4:30 p.m. ET on November 27, 2019.
 
A live audio webcast will be available through the Events and Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 90 days.
 
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that mirrors some applications similar to CT or MRI, but at 50X lower cost, at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com
 
 
 
 
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as obtaining a CE Mark and commercializing the TAEUS device; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
 
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
 
Media & Investor Relations Contact:
MacDougall
Christi Waarich
(781) 235-3060
endra@macbiocom.com
www.macbiocom.com
 
 
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Balance Sheets
 
 
 
September 30,
 
 
December 31,
 
Assets
 
2019
 
 
2018
 
Assets
 
(Unaudited)
 
 
 
 
Cash
 $2,275,302 
 $6,471,375 
Prepaid expenses
  206,658 
  145,424 
Inventory
  127,831 
  59,444 
Other current assets
  366,390 
  273,315 
Total Current Assets
  2,976,181 
  6,949,558 
Other Assets
    
    
Fixed assets, net
  218,798 
  273,233 
Right of use assets
  420,488 
  - 
Total Assets
 $3,615,467 
 $7,222,791 
 
    
    
Liabilities and Stockholders’ Equity
    
    
Current Liabilities:
    
    
Accounts payable and accrued liabilities
 $1,198,487 
 $974,583 
Convertible notes payable, net of discount
  590,026 
  - 
Lease liabilities, current portion
  65,295 
  - 
Total Current Liabilities
  1,853,808 
  974,583 
 
    
    
Long Term Liabilities:
    
    
Lease liabilities
  358,915 
  - 
Total Long Term Liabilities
  358,915 
  - 
 
    
    
Total Liabilities
  2,212,723 
  974,583 
 
    
    
Stockholders’ Equity
    
    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding
  - 
  - 
Common stock, $0.0001 par value; 50,000,000 shares authorized; 7,516,875 and 7,422,642 shares issued and outstanding
  751 
  742 
Additional paid in capital
  37,590,359 
  33,939,162 
Accumulated deficit
  (36,188,366)
  (27,691,696)
Total Stockholders’ Equity
  1,402,744 
  6,248,208 
Total Liabilities and Stockholders’ Equity
 $3,615,467 
 $7,222,791 
 
 
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
 
 
 
Three Months Ended
 
 
Three Months Ended
 
 
Nine Months Ended
 
 
Nine Months Ended
 
 
 
September 30,
 
 
September 30,
 
 
September 30,
 
 
September 30,
 
 
 
2019
 
 
2018
 
 
2019
 
 
2018
 
Revenue
 $- 
 $- 
 $- 
 $6,174 
 
    
    
    
    
Cost of Goods Sold
  - 
  - 
  - 
  - 
 
    
    
    
    
Gross Profit
 $- 
 $- 
 $- 
 $6,174 
 
    
    
    
    
Operating Expenses
    
    
    
    
Research and development
  1,468,441 
  1,162,911 
  4,546,746 
  3,671,490 
Sales and marketing
  100,203 
  72,179 
  245,364 
  220,713 
General and administrative
  1,071,889 
  832,884 
  2,920,815 
  2,842,631 
Impairment of inventory
  - 
  287,541 
  - 
  287,541 
Total operating expenses
  2,640,533 
  2,355,515 
  7,712,925 
  7,022,375 
 
    
    
    
    
Operating loss
  (2,640,533)
  (2,355,515)
  (7,712,925)
  (7,016,201)
 
    
    
    
    
Other Expenses
    
    
    
    
Amortization of debt discount
  (728,417)
  (377,606)
  (728,417)
  (383,428)
Other expense
  (44,612)
  (25,455)
  (55,328)
  (31,022)
Total other expenses
  (773,029)
  (403,061)
  (783,745)
  (414,450)
 
    
    
    
    
Loss from operations before income taxes
  (3,413,562)
  (2,758,576)
  (8,496,670)
  (7,430,651)
 
    
    
    
    
Provision for income taxes
  - 
  - 
  - 
  - 
 
    
    
    
    
Net Loss
 $(3,413,564)
 $(2,758,576)
 $(8,496,670)
 $(7,430,651)
 
    
    
    
    
Net loss per share – basic and diluted
 $(0.46)
 $(0.70)
 $(1.14)
 $(1.89)
 
    
    
    
    
Weighted average common shares – basic and diluted
  7,428,788 
  3,927,933 
  7,424,713 
  3,924,662 
 
 
 
 
ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
 
 
Nine Months Ended
 
 
Nine Months Ended
 
 
 
September 30,
 
 
September 30,
 
 
 
2019
 
 
2018
 
Cash Flows from Operating Activities
 
 
 
 
 
 
Net loss
 $(8,496,670)
 $(7,430,651)
Adjustments to reconcile net loss to net cash used in operating activities:
    
    
Depreciation and amortization
  59,673 
  48,246 
Common stock, options and warrants issued for services
  1,020,300 
  1,060,012 
Amortization of debt discount
  728,417 
  383,428 
Impairment of inventory
  - 
  287,541 
Changes in operating assets and liabilities:
    
    
Increase in accounts receivable
  - 
  (5,425)
Increase in prepaid expenses
  (61,234)
  (260,550)
Increase in inventory
  (68,387)
  (95,861)
Increase in other asset
  (93,075)
  (6,918)
Increase in accounts payable and accrued liabilities
  229,640 
  220,124 
Net cash used in operating activities
  (6,681,336)
  (5,800,054)
 
    
    
Cash Flows from Investing Activities:
    
    
Purchases of fixed assets
  (5,238)
  (100,000)
Net cash used in investing activities
  (5,238)
  (100,000)
 
    
    
Cash Flows from Financing Activities
    
    
Proceeds from senior secured convertible promissory notes, net of fees
  2,490,501 
  935,300 
Net cash provided by financing activities
  2,490,501 
  935,300 
 
    
    
Net Increase/(Decrease) in cash
  (4,196,073)
  (4,964,754)
 
    
    
Cash, beginning of period
  6,471,375 
  5,601,878 
 
    
    
Cash, end of period
 $2,275,302 
 $637,124 
 
    
    
Supplemental disclosures of cash items:
    
    
Interest paid
 $- 
 $- 
Income tax paid
 $- 
 $- 
 
    
    
Supplemental disclosures of non-cash items:
    
    
Discount on convertible notes
 $2,490,501 
 $587,541 
Conversion of convertible notes and accrued interest
 $140,405 
 $50,000 
Right of use asset
 $420,488 
 $- 
Lease liability
 $424,210 
 $-